ATE447610T1 - Kristalliner vap-1 und verwendung - Google Patents

Kristalliner vap-1 und verwendung

Info

Publication number
ATE447610T1
ATE447610T1 AT04734701T AT04734701T ATE447610T1 AT E447610 T1 ATE447610 T1 AT E447610T1 AT 04734701 T AT04734701 T AT 04734701T AT 04734701 T AT04734701 T AT 04734701T AT E447610 T1 ATE447610 T1 AT E447610T1
Authority
AT
Austria
Prior art keywords
vap
crystalline
usage
present
crystalline vap
Prior art date
Application number
AT04734701T
Other languages
English (en)
Inventor
Tiina Salminen
Tomi Airenne
Mark Johnson
Heidi Kidron
Yvonne Nymalm-Rejstroem
Annu Soederholm
David Smith
Marjo Pihlavisto
Lenita Viitanen
Olli Pentikaeinen
Tommi Nyroenen
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20030786A external-priority patent/FI20030786A0/fi
Priority claimed from FI20040271A external-priority patent/FI20040271A0/fi
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Application granted granted Critical
Publication of ATE447610T1 publication Critical patent/ATE447610T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
AT04734701T 2003-05-26 2004-05-25 Kristalliner vap-1 und verwendung ATE447610T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030786A FI20030786A0 (fi) 2003-05-26 2003-05-26 VAP-1:n uusi käyttö
FI20040271A FI20040271A0 (fi) 2004-02-20 2004-02-20 Kiteinen VAP-1 ja sen käyttö
PCT/FI2004/000318 WO2004104191A1 (en) 2003-05-26 2004-05-25 Crystalline vap-1 and uses thereof

Publications (1)

Publication Number Publication Date
ATE447610T1 true ATE447610T1 (de) 2009-11-15

Family

ID=33477699

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04734701T ATE447610T1 (de) 2003-05-26 2004-05-25 Kristalliner vap-1 und verwendung

Country Status (11)

Country Link
US (2) US7499847B2 (de)
EP (1) EP1633861B1 (de)
JP (1) JP2007509605A (de)
AT (1) ATE447610T1 (de)
AU (1) AU2004241060B2 (de)
CA (1) CA2526675A1 (de)
DE (1) DE602004023939D1 (de)
DK (1) DK1633861T3 (de)
ES (1) ES2335769T3 (de)
NZ (1) NZ543430A (de)
WO (1) WO2004104191A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20040270A0 (fi) * 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
EP2084518A4 (de) * 2007-01-12 2014-04-16 Veronica James Biometrische diagnose
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
WO2017098236A1 (en) 2015-12-07 2017-06-15 Proximagen Limited Vap-1 inhibitors for treating pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580780A (en) 1992-06-09 1996-12-03 Jalkanen; Sirpa Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies
KR100533911B1 (ko) * 1997-05-23 2005-12-06 바이오티에 세라피스 코포레이션 아민 산화효소의 활성을 갖는 혈관 점착 단백질-1
TR200002271T2 (tr) * 1998-02-06 2000-11-21 Ilexus Pty Limited Fc alıcılarının üç boyutlu yapıları ve modelleri ve bunların kullanımı
JP2004502682A (ja) 2000-07-05 2004-01-29 バイオティ　セラピーズ　コーポレイション 銅含有アミン・オキシダーゼの阻害剤
US7167801B2 (en) * 2001-07-12 2007-01-23 Boehringer Ingelheim (Canada) Ltd. Method of identifying potential inhibitors of human papillomavirus protein E2 using x-ray atomic coordinates
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
FI20040270A0 (fi) 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset

Also Published As

Publication number Publication date
CA2526675A1 (en) 2004-12-02
US20070093646A1 (en) 2007-04-26
DE602004023939D1 (de) 2009-12-17
HK1086591A1 (en) 2006-09-22
DK1633861T3 (da) 2010-03-22
AU2004241060A1 (en) 2004-12-02
NZ543430A (en) 2008-06-30
US20110021760A1 (en) 2011-01-27
US7499847B2 (en) 2009-03-03
EP1633861A1 (de) 2006-03-15
WO2004104191A8 (en) 2006-08-17
AU2004241060B2 (en) 2009-07-23
ES2335769T3 (es) 2010-04-05
EP1633861B1 (de) 2009-11-04
WO2004104191A1 (en) 2004-12-02
JP2007509605A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE552834T1 (de) Zubereitung von 1,6-disubstituierten azabenzimidazolen als kinasehemmer
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
NO20071127L (no) Triazoloftalaziner
BRPI0606379A2 (pt) triazolftalazinas
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
UA93531C2 (en) Novel hydrogen sulfate salt
NO20055741L (no) Nye kjemiske forbindelser
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
DE602004031458D1 (de) Verfahren zur erhöhung der refinerproduktionsrate und/oder verringerung der spezifischen energie des aufschliessens von holz
DE60329326D1 (de) Tace inhibitoren
ATE447610T1 (de) Kristalliner vap-1 und verwendung
DE602005024572D1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
DE10342670A1 (de) Isoliertes Photoprotein mtClytin, sowie dessen Verwendung
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
DE502004002460D1 (de) Verwendung von copolymerisaten als hilfsmittel für die lederherstellung
ATE390427T1 (de) Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1633861

Country of ref document: EP

REN Ceased due to non-payment of the annual fee